Diabetes drugmaker Novo Nordisk (NYSE:NVO) posted Street-beating second quarter results today, lifting its full-year sales forecast despite lingering concerns relating to U.S. drug pricing pressures. Last year, the Danish company saw shares drop more than 40% after it slashed its long-term operating profit forecasts, citing price pressures in the U.S. market. Today, Novo Nordisk raised its […]
Novo Nordisk
Novo Nordisk recalls cartridge holders in insulin delivery devices
Novo Nordisk (NYSE:NVO) launched a recall yesterday of insulin cartridge holders used in select batches of NovoPen Echo insulin delivery devices. The company said the cartridge holders could crack or break upon exposure to certain chemicals. Using a NovoPen Echo with a cracked or broken cartridge holder could result in the device delivering a lower dose […]
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Novo Nordisk (NYSE:NVO) touted data today from 2 Phase IIIb trials comparing Tresiba insulin degludec to insulin glargine in adults with Type I and Type II diabetes. The results were published in the Journal of the American Medical Association. The Switch trials are the 1st double-blinded insulin trials to compare the hypoglycemia rates and risks in patients […]
FDA committee supports Nordisk’s cardiovascular risk claim for Victoza label
Novo Nordisk (NYSE:NVO) shares ticked up 1% earlier this week after an advisory committee for the FDA voted to recommend that the company’s cardiovascular risk reduction claim be added to its Victoza (liraglutide) label. The discussions among committee members involved data from the 9,300-patient Leader trial, which involved people with Type II diabetes at high risk […]
ADA 2017 Roundup: Photo ban causes stir among conference attendees
Many scientific conferences have embraced the technological age, creating hashtags for attendees to share content on Twitter and engage with one another. Some conferences even acknowledge attendees with powerful social media presences by giving them special ribbons and including their Twitter handles on their name badges. But at this year’s meeting of the American Diabetes […]
Novo Nordisk seeks to include cardiovascular data in Tresiba insulin label
Novo Nordisk (NYSE:NVO) said today that it submitted a supplemental application to the FDA, asking to include cardiovascular data on the label of its Tresiba insulin degludec. The Danish insulin-maker asked to include data specifically from the Devote trial, which evaluated the cardiovascular safety of Tresiba compared to insulin glargine in patients with Type II diabetes. The […]
Novelion CEO leaves Nordisk board due to potential conflict of interest | Personnel Moves – May 16, 2017
Novo Nordisk (NYSE:NVO) said this week that the CEO of Canadian biotech Novelion Therapeutics, Mary Szela, left Nordisk’s board effective immediately due to a “potential conflict of interest”. Szela’s departure follows Novelion’s decision to expand into non-alcoholic steatohepatitis, also known as fatty liver, according to a Nordisk spokeswoman. As the Danish drugmaker faces increasing pricing pressure […]
Sanofi ties drug price increases to healthcare inflation
Insulin makers have faced questioning this year for their drug pricing practices – a class-action lawsuit filed in the U.S. District Court of Massachusetts in January alleges that Sanofi (NYSE:SNY), Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) conspired to raise their list prices to get access to pharmacy benefit managers’ preferred lists, instead of competing with each other […]
Novo Nordisk launches Xultophy diabetes therapy in U.S.
Novo Nordisk (NYSE:NVO) said today that it launched its Type II diabetes combination therapy, Xultophy, in pharmacies across the U.S. The injection is a combination of insulin degludec and liraglutide that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. In clinical trials, Xultophy reduced […]
Nordisk shares climb after Q1 beat
Shares in Novo Nordisk (NYSE:NVO) rose today after the insulin-maker met expectations on Wall Street with its 1st quarter results. The Denmark-based company posted profits of $1.49 billion, or 60¢ per share, on sales of $4.18 billion for the 3 months ended March 31, for bottom-line growth of 7% on sales growth of 5% compared with […]
